Repeated Low-Level Red-Light Therapy & Orthokeratology in Fast-progressing

Status Recruiting

Clinical Trial Summary

The purpose of this multicenter randomized clinical trial is to evaluate the adjunctive effect of repeated low-level red-light therapy (RLRL) and orthokeratology (ortho-k) on myopia control in ortho-k non-responders who have undergone ortho-k treatment but were still experiencing fast myopia progression.

Clinical Trial Description

Myopia constitutes a major threat to personal health globally for its increased prevalence. Moreover, its dose-related association with irreversible blindness complications such as myopic macular degeneration have been demonstrated. It is crucial to look for effective ways to control myopia in children to reduce risk of myopic pathologies in later life. Orthokeratology (ortho-k) is the first-line optical method in myopia control, resulting in slowing axial elongation by 43-63%. However, results after ortho-k treatment vary among individuals. Methods with more accurate efficacy and wider application to slowing down myopia progression, especially for myopia with limited ortho-k response, are still urgently required. Repeated low-level red-light (RLRL) therapy is an innovative and non-invasive therapeutic treatment for a variety of eye diseases. Our previous clinical study suggested RLRL could effectively retard myopia progression without clinically observable side effects. The purpose of this study is to evaluate the adjunctive effect of RLRL and ortho-k on myopia control in ortho-k non-responders using a multicenter randomized controlled trial design. Ortho-k non-responders are defined as who have continuously undergone ortho-k treatment but were still experiencing fast myopia progression. The subjects will be randomly assigned to either experimental group (RLRL and ortho-k) or control group (ortho-k). Their axial length will be monitored over one year. Changes in axial length in the two groups will be compared. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04722874
Study type	Interventional
Source	Zhongshan Ophthalmic Center, Sun Yat-sen University
Contact	Xiao Yang, Professor
Phone	+86-020-87330348
Email	1394392659@qq.com
Status	Recruiting
Phase	N/A
Start date	March 14, 2021
Completion date	June 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05414994` - Assessment of the Ocular Microbiome in Health and Disease
Active, not recruiting	`NCT04271709` - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)	N/A
Completed	`NCT02811692` - Study for Collection of Aflibercept Data in Routine Practice
Recruiting	`NCT06045299` - Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia	Phase 3
Recruiting	`NCT01521065` - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	Phase 2
Completed	`NCT04799704` - Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
Recruiting	`NCT05876689` - Swept Source OCT Imaging With the DREAM VG-OCT
Active, not recruiting	`NCT04123626` - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene	Phase 1/Phase 2
Recruiting	`NCT04150432` - Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children	N/A
Not yet recruiting	`NCT05550740` - Repeated Low-Level Red-Light Therapy for Shortening Axial Length	N/A
Completed	`NCT02332343` - Sparing of the Fovea in Geographic Atrophy Progression	N/A
Completed	`NCT01727973` - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy	Phase 1/Phase 2
Terminated	`NCT01225146` - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)	Phase 1
Completed	`NCT00333203` - Next Generation Ophthalmic Irrigating Solution Posterior Segment Study	Phase 3
Not yet recruiting	`NCT05565547` - Multimodal Equipment for Teleophthalmology Assessment (META)
Recruiting	`NCT05158699` - Effectiveness of Periocular Drug Injection in CATaract Surgery	Phase 3
Recruiting	`NCT06451172` - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis	Early Phase 1
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Completed	`NCT05211089` - Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
Not yet recruiting	`NCT06070467` - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Repeated Low-Level Red-Light Therapy and Orthokeratology in Fast-progressing Myopia Control

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms